Plus Products Inc. has expanded its recently launched wellness and relief brand, PLUS CBDRelief, with the introduction of a Pomegranate 1:1 CBD to THC ratio product.

The new PLUS CBDRelief 1:1 Pomegranate gummy, with 5mg of THC and 5mg of CBD per serving, is made with real California pomegranates, which contain ellagitannins, unique antioxidants found in pomegranates that are associated with anti-inflammatory pathways. 

The new product joins the initial PLUS CBDRelief lineup, which includes a 9:1 Tropical Mango gummy with 9mg of CBD and 1mg of THC per serving, and an 18:1 Tart Cherry gummy with 18mg of CBD and 1mg of THC per serving.

“Last year we partnered with market structure research firm, HJ Rak & Associates, and found that when consumers used cannabis, over one-third of the time it was to address pain, stress or anxiety,” says Jake Heimark, co-founder and CEO. “We sought to satisfy this consumer need state by launching the PLUS CBDRelief line, which 80 percent of our California retail distribution network has picked up since its launch earlier this year. After what we believe was a successful rollout, we are excited to expand our wellness and relief portfolio with this new product introduction.”

PLUS CBDRelief products are specifically formulated with blends of CBD and THC to help reduce chronic subclinical inflammation, provide full-body relief and promote a calm state of mind.

“Research suggests that people are looking to cannabis as a holistic tool for relief,” said Dr. Ari Mackler, PLUS chief scientific officer. “It’s exciting to leverage rigorous science to formulate great products that enable people to help themselves. Cannabis research is progressing quickly, and we are driving our product portfolio with innovative science and technologies that we believe will support our customers’ health and wellness goals.”

PLUS CBDRelief 1:1 Pomegranate gummies are expected to be available at licensed retailers across California.

Want more legal cannabis market news and information?
Join Cannabis Products on Facebook, Twitter, and LinkedIn today!